Adjuvant endocrine therapy for early breast cancer: The story so far

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Aromatase inhibitors (AIs) have largely replaced tamoxifen as adjuvant hormonal therapy for postmenopausal women with early breast cancer. While tamoxifen is effective in reducing breast cancer recurrence and mortality, recent data indicate two peaks of early, mostly distant metastatic recurrences in patients receiving tamoxifen, and AIs have proven more effective in reducing recurrence. As distant recurrence has been associated with poorer survival and death, reduction in this type of early recurrence event may lead to improved survival over the long term. Recent data from major clinical trials are beginning to bear out this contention.

Original languageEnglish (US)
Pages (from-to)433-442
Number of pages10
JournalCancer Investigation
Issue number4
StatePublished - Apr 2010


  • Aromatase inhibitors
  • Breast cancer
  • Recurrence
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant endocrine therapy for early breast cancer: The story so far'. Together they form a unique fingerprint.

Cite this